# Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

> **NCT07648823** · EARLY_PHASE1 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 5 (estimated)

## Conditions studied

- Recurrent Glioblastoma (WHO-Grade IV Glioma)
- Recurrent Glioblastoma
- Glioblastoma (GBM)
- Recurrent Glioblastoma IDH Wildtype

## Interventions

- **DRUG:** [177Lu]Lu-XT771

## Key facts

- **NCT ID:** NCT07648823
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-20
- **Primary completion:** 2027-06-20
- **Final completion:** 2028-06-01
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648823, "Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*